StockData

Bionano Genomics vs Precipio

BNGO and PRPO side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNGO and PRPO compare

Precipio is the larger company, worth 3.2 times as much as Bionano Genomics ($35.7M against $11.1M).

Precipio grew revenue faster over the last twelve months (28.0% versus 10.0% for Bionano Genomics).

Bionano Genomics scores higher on the StockData Score (12 against 5 for Precipio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNGOPRPO
Size and price
Market cap$11.1M$35.7M
Share price$0.940$19.96
Change, 1 year−36.1%2.3%
Change, 5 years−100.0%−47.7%
Beta (5Y)1.160.31
Employees9761
StockData Score
Total score12 (better)5
Valuation score3 (better)1
Growth score3 (better)2
Performance score1 (better)0
Health score5 (better)2
Dividend score00
Valuation
P/S0.4× (better)1.3×
P/B0.4×–
P/FCF–45.3×
FCF yield–2.2%
Fair value$5.47–
Margin of safety82.8%–
Growth
Revenue growth (TTM)10.0%28.0% (better)
Revenue growth, 5Y average27.4%31.6% (better)
Profitability
Gross margin47.5% (better)44.1%
Operating margin−107%−5.7% (better)
Net margin−107%–
FCF margin–2.9%
Return on equity−83.6%–
Return on invested capital−100%–
Financial health
Debt / equity0.00–
Current ratio2.48 (better)1.77
Altman Z-score−22.44−2.40 (better)
Piotroski F-score67 (better)
Dividends and buybacks
Buyback yield−145%–
Shareholder yield−145%0.00% (better)
Ownership
Held by institutions6.0%8.8%
Held by insiders1.8%20.4%
Insider net buying, 12 months$9.7K (better)−$98.8K
Short interest, % of float12.0%3.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.